{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:10:05Z","timestamp":1780366205027,"version":"3.54.1"},"reference-count":7,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,11,20]],"date-time":"2013-11-20T00:00:00Z","timestamp":1384905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>On 3 <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>eptember 2012, the <jats:styled-content style=\"fixed-case\">UK M<\/jats:styled-content>edicines and <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>ealthcare <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>roducts <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>egulatory <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>gency (<jats:styled-content style=\"fixed-case\">MHRA<\/jats:styled-content>) notified healthcare professionals of immediate changes to the intravenous acetylcysteine license terms, altering the treatment pathway for paracetamol poisoning. We sought to evaluate awareness of this amongst healthcare professionals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We surveyed doctors, nurses and pharmacists in the 1\u201312 week period following the implementation date.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty\u2010four individuals completed the survey in paper form (response rate 86%) and 220 in electronic form (response rate unknown). The resulting sample of 264 individuals was drawn from 41 institutions, and included 143 doctors, 58 pharmacists and 50 nurses. Of these individuals, 157 (59%) were aware of the changes, and 133 (50%) had adopted them in practice. Awareness differed between healthcare professions (<jats:italic>P<\/jats:italic>\u2009=\u20090.001) and specialties (<jats:italic>P<\/jats:italic>\u2009=\u20090.002). For respondents aware of the changes, the main sources of information were alerts issued internally (reported by 57%), from the <jats:styled-content style=\"fixed-case\">MHRA<\/jats:styled-content> (25%) and from other professional bodies (24%). The proportion of individuals who reported receiving practical implementation instructions (e.g. a protocol) was higher among respondents who had changed their practice than for those who had not (86 <jats:italic>vs.<\/jats:italic> 25%, respectively; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Less than two\u2010thirds of healthcare professionals in specialties managing patients with paracetamol poisoning were aware of important changes to its treatment pathway in the 12 weeks after they took effect, and only half had adopted them in practice. Alternative communication strategies should be explored to improve dissemination of similar information from the <jats:styled-content style=\"fixed-case\">MHRA<\/jats:styled-content> and other medicines regulators in the future.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.12111","type":"journal-article","created":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T21:22:43Z","timestamp":1363296163000},"page":"946-950","source":"Crossref","is-referenced-by-count":5,"title":["Dissemination and uptake of a new treatment pathway for paracetamol poisoning in the <scp>UK<\/scp>: a survey of healthcare professionals"],"prefix":"10.1111","volume":"76","author":[{"given":"Andrew W.","family":"Hitchings","sequence":"first","affiliation":[{"name":"Clinical Toxicology Guy's and St Thomas' NHS Foundation Trust and King's Health Partners  London UK"},{"name":"Clinical Pharmacology St George's, University of London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Wood","sequence":"additional","affiliation":[{"name":"Clinical Toxicology Guy's and St Thomas' NHS Foundation Trust and King's Health Partners  London UK"},{"name":"King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul I.","family":"Dargan","sequence":"additional","affiliation":[{"name":"Clinical Toxicology Guy's and St Thomas' NHS Foundation Trust and King's Health Partners  London UK"},{"name":"King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,11,20]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"National Poisons Information Service.Annual Report 2011\/2012.2012. Health Protection Agency [online]. Available athttp:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1317136044886(last accessed 9 January 2013)."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60274-7"},{"key":"e_1_2_8_4_1","unstructured":"DuffGW.Paracetamol overdose: new guidance on use of intravenous acetylcysteine. Direct Healthcare Professional Communication. Commission on Human Medicines 03\/09\/2012. Available athttp:\/\/www.mhra.gov.uk\/home\/groups\/pl\u2010p\/documents\/drugsafetymessage\/con178654.pdf(last accessed 9 January 2013)."},{"key":"e_1_2_8_5_1","unstructured":"Medicines and Healthcare Products Regulatory Agency.Paracetamol overdose: simplification of the use of intravenous acetylcysteine question and answer document.2012. Available athttp:\/\/www.mhra.gov.uk\/home\/groups\/pl\u2010p\/documents\/drugsafetymessage\/con178651.pdf(last accessed 9 January 2013)."},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2011.594054"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e318245a160"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","unstructured":"HaynesL ServiceO GoldacreB TorgersonD.Test learn adapt: developing public policy with randomised controlled trials. Cabinet Office Behavioural Insights Team2012. Available athttp:\/\/www.cabinetoffice.gov.uk\/sites\/default\/files\/resources\/TLA\u20101906126.pdf(last accessed 26 March 2013).","DOI":"10.2139\/ssrn.2131581"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12111","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T21:37:02Z","timestamp":1696282622000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,20]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1111\/bcp.12111"],"URL":"https:\/\/doi.org\/10.1111\/bcp.12111","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,20]]}}}